Lexicon Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Lexicon Pharmaceuticals Inc cash flow-to-debt ratio. Lexicon Pharmaceuticals Inc (LXRX) has a Cash Flow-to-Debt Ratio of -0.22x as of March 2026, meaning its operating cash flow of $-14.73 Million could theoretically repay 0% of its total liabilities ($65.96 Million) in one year. Check LXRX cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Lexicon Pharmaceuticals Inc (1999–2025)
Cash flow-to-debt ratio of Lexicon Pharmaceuticals Inc from 1999 to 2025. Historical debt coverage capacity for Lexicon Pharmaceuticals Inc across 27 annual periods. Check Lexicon Pharmaceuticals Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Lexicon Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (1999–2025)
Lexicon Pharmaceuticals Inc cash flow-to-debt ratio by year from 1999 to 2025. Year-by-year debt coverage analysis for Lexicon Pharmaceuticals Inc. For the full cash flow conversion analysis, see Lexicon Pharmaceuticals Inc (LXRX) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.88x | $-67.85 Million | $77.45 Million | ▲ +25.3% |
| 2024 | -1.17x | $-178.78 Million | $152.47 Million | ▲ +1.3% |
| 2023 | -1.19x | $-161.90 Million | $136.32 Million | ▼ -3.2% |
| 2022 | -1.15x | $-88.85 Million | $77.17 Million | ▲ +69.2% |
| 2021 | -3.73x | $-87.02 Million | $23.31 Million | ▼ -23.8% |
| 2020 | -3.02x | $-142.97 Million | $47.42 Million | ▼ -896.4% |
| 2019 | 0.38x | $113.81 Million | $300.61 Million | ▲ +179.1% |
| 2018 | -0.48x | $-148.61 Million | $310.54 Million | ▲ +0.8% |
| 2017 | -0.48x | $-185.39 Million | $384.44 Million | ▲ +12.6% |
| 2016 | -0.55x | $-175.63 Million | $318.22 Million | ▼ -210.2% |
| 2015 | 0.50x | $184.78 Million | $368.98 Million | ▲ +224.1% |
| 2014 | -0.40x | $-75.62 Million | $187.36 Million | ▲ +53.9% |
| 2013 | -0.88x | $-91.08 Million | $104.00 Million | ▲ +2.6% |
| 2012 | -0.90x | $-94.46 Million | $105.10 Million | ▼ -35.9% |
| 2011 | -0.66x | $-87.94 Million | $132.94 Million | ▲ +3.7% |
| 2010 | -0.69x | $-82.37 Million | $119.86 Million | ▲ +27.2% |
| 2009 | -0.94x | $-89.02 Million | $94.26 Million | ▲ +35.1% |
| 2008 | -1.46x | $-95.60 Million | $65.68 Million | ▼ -62.0% |
| 2007 | -0.90x | $-74.32 Million | $82.72 Million | ▼ -65.4% |
| 2006 | -0.54x | $-56.91 Million | $104.77 Million | ▼ -408.0% |
| 2005 | 0.18x | $23.44 Million | $132.91 Million | ▲ +137.7% |
| 2004 | -0.47x | $-42.26 Million | $90.39 Million | ▼ -614.8% |
| 2003 | -0.07x | $-7.72 Million | $117.98 Million | ▲ +92.8% |
| 2002 | -0.90x | $-28.79 Million | $31.87 Million | ▼ -8.6% |
| 2001 | -0.83x | $-17.99 Million | $21.62 Million | ▼ -624.1% |
| 2000 | -0.11x | $-1.50 Million | $13.06 Million | ▲ +83.1% |
| 1999 | -0.68x | $-9.60 Million | $14.10 Million | — |